‘This is only the beginning of the GLP-1 journey in India’: Vikrant Shrotriya, MD of Novo Nordisk India
- Posted on July 10, 2026
- By Financial Express
- 0 Views
- 1 min read
‘This is only the beginning of the GLP-1 journey in India’: Vikrant Shrotriya, MD of Novo Nordisk India
Novo Nordisk India MD Vikrant Shrotriya discusses navigating the post-patent semaglutide generic influx, the massive underpenetration of GLP-1 therapies, and how their once-weekly insulin, Awiqli, could double India’s insulin market.
